Tag: ovarianCancer

Articles

• BRCA1 and BRCA2 mutation carriers
• Lobular breast cancer and LCIS characteristics

News

07/22/22

Mortality after some second cancers may be higher for breast cancer survivors

02/09/14

Young birth control pill use heightens BC risk in BRCA1 carriers

01/10/12

Father's breast cancer or BRCA mutation influences daughter's risk

10/18/11

Previous appendectomy linked to cancer in Jewish BRCA carriers

Studies

• Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers Cite
  Allen I, Hassan H, Walburga Y, Huntley C, Loong L, Rahman T, et al. Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2024; 10.1200/jco.24.01146
• Risk-reducing salpingectomy with delayed oophorectomy to prevent ovarian cancer in women with an increased inherited risk: insights into an alternative strategy Cite
  Gootzen T, Steenbeek M, van Bommel M, IntHout J, Kets C, Hermens R, et al. Risk-reducing salpingectomy with delayed oophorectomy to prevent ovarian cancer in women with an increased inherited risk: insights into an alternative strategy. Familial Cancer. Springer Science and Business Media LLC; 2024; 10.1007/s10689-024-00412-0
• Association of Levonorgestrel-Releasing Intrauterine Device with Gynecologic and Breast Cancers: National Cohort Study in Sweden Cite
  Yi H, Zhang N, Huang J, Zheng Y, Hong Qh, Sundquist J, et al. Association of Levonorgestrel-Releasing Intrauterine Device with Gynecologic and Breast Cancers: National Cohort Study in Sweden. American Journal of Obstetrics and Gynecology. Elsevier BV; 2024; 10.1016/j.ajog.2024.05.011
• Abstract PO3-11-10: Second primary non-breast cancers in young breast cancer survivors Cite
  Zhang B, Brantley K, Rosenberg S, Kirkner G, Collins L, Ruddy K, et al. Abstract PO3-11-10: Second primary non-breast cancers in young breast cancer survivors. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:PO3-11-10-PO3-11-10 10.1158/1538-7445.sabcs23-po3-11-10
• Abstract 7321: Second primary cancer risks following breast cancer in BRCA1/2 pathogenic variant carriers Cite
  Allen I, Hassan H, Walburga Y, Huntley C, Loong L, Rahman T, et al. Abstract 7321: Second primary cancer risks following breast cancer in BRCA1/2 pathogenic variant carriers. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:7321-7321 10.1158/1538-7445.am2024-7321
• Cancer risks among first-degree relatives of women with a genetic predisposition to breast cancer Cite
  Xiao Q, Mao X, Ploner A, Grassmann F, Rodriguez J, Eriksson M, et al. Cancer risks among first-degree relatives of women with a genetic predisposition to breast cancer. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2024; 10.1093/jnci/djae030
• Harnessing Sulforaphane Potential as a Chemosensitizing Agent: A Comprehensive Review Cite
  Sailo BL, Liu L, Chauhan S, Girisa S, Hegde M, Liang L, et al. Harnessing Sulforaphane Potential as a Chemosensitizing Agent: A Comprehensive Review. Cancers. MDPI AG; 2024; 16:244 10.3390/cancers16020244
• Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC) Cite
  Madrigal LF, Garcé MYR, Ruiz FJJ. Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC). Current Problems in Cancer. Elsevier BV; 2023;:101008 10.1016/j.currproblcancer.2023.101008
• Assessing the impact of contraceptive use on cancer risk among women of reproductive age – a systematic review Cite
  Jahanfar S, Mortazavi J, Lapidow A, Cu C, Abosy JA, Morris K, et al. Assessing the impact of contraceptive use on cancer risk among women of reproductive age – a systematic review. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-3191980/v1
• Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer Cite
  Öfverholm A, Törngren T, Rosén A, Arver B, Einbeigi Z, Haraldsson K, et al. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer. BMC Cancer. Springer Science and Business Media LLC; 2023; 23 10.1186/s12885-023-11229-y
• Risk of estrogen receptor–specific breast cancer by family history of estrogen receptor subtypes and other cancers Cite
  Wang Q, Zhang Y, Zeng E, Grassmann F, He W, Czene K. Risk of estrogen receptor–specific breast cancer by family history of estrogen receptor subtypes and other cancers. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2023; 10.1093/jnci/djad104
• Evidence-based identification of breast cancer and associated ovarian and uterus cancer risk components in source waters from high incidence area in the Pearl River Basin, China Cite
  Peng S, Dong S, Gong C, Chen X, Du H, Zhan Y, et al. Evidence-based identification of breast cancer and associated ovarian and uterus cancer risk components in source waters from high incidence area in the Pearl River Basin, China. Science of The Total Environment. Elsevier BV; 2023;:166060 10.1016/j.scitotenv.2023.166060
• Risk Factors for Developing Both Primary Breast and Primary Ovarian Cancer: A Systematic Review Cite
  Ferris JS, Morgan DA, Tseng AS, Terry MB, Ottman R, Hur C, et al. Risk Factors for Developing Both Primary Breast and Primary Ovarian Cancer: A Systematic Review. Critical Reviews in Oncology/Hematology. Elsevier BV; 2023;:104081 10.1016/j.critrevonc.2023.104081
• Novel Iron Chelator SK4 Drives Cytotoxicity through Inhibiting Mitochondrial Metabolism in Ovarian and Triple Negative Breast Cancer Cell Lines Cite
  Abdelaal G, Carter A, Cheung W, Panayiotidis M, Racey S, Tétard D, et al. Novel Iron Chelator SK4 Drives Cytotoxicity through Inhibiting Mitochondrial Metabolism in Ovarian and Triple Negative Breast Cancer Cell Lines. Biomedicines. MDPI AG; 2023; 11:2073 10.3390/biomedicines11072073
• Risk of ER-specific breast cancer by family history of ER subtypes and other cancers Cite
  Wang Q, Zhang Y, Zeng E, Grassmann F, He W, Czene K. Risk of ER-specific breast cancer by family history of ER subtypes and other cancers. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2023; 10.1093/jnci/djad104
• Familial aggregation of early‐onset cancers in early‐onset breast cancer families Cite
  Rantala JNJ, Heikkinen SMM, Hirvonen EM, Tanskanen T, Malila NK, Pitkäniemi JM. Familial aggregation of early‐onset cancers in early‐onset breast cancer families. International Journal of Cancer. Wiley; 2023; 10.1002/ijc.34538
• Risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer: a single-institution 10-year experience Cite
  Nagashima M, Ishikawa T, Asami Y, Hirose Y, Shimada K, Miyagami S, et al. Risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer: a single-institution 10-year experience. Japanese Journal of Clinical Oncology. Oxford University Press (OUP); 2023; 10.1093/jjco/hyad020
• Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in BRCA Carriers: A Systematic Review and Meta-Analysis Cite
  Gaba F, Blyuss O, Tan A, Munblit D, Oxley S, Khan K, et al. Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in BRCA Carriers: A Systematic Review and Meta-Analysis. Cancers. MDPI AG; 2023; 15:1625 10.3390/cancers15051625
• The risks of cancer in older women with BRCA pathogenic variants: How far have we come? Cite
  Metcalfe KA, Gronwald J, Tung NM, McCuaig JM, Eisen A, Elser C, et al. The risks of cancer in older women with BRCA pathogenic variants: How far have we come?. Cancer. Wiley; 2022; 129:901-907 10.1002/cncr.34615
• Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis Cite
  Allen I, Hassan H, Sofianopoulou E, Eccles D, Turnbull C, Tischkowitz M, et al. Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01610-x
• The Self-Administered Use of Complementary and Alternative Medicine (CAM) Supplements and Antioxidants in Cancer Therapy and the Critical Role of Nrf-2—A Systematic Review Cite
  Krejbich P, Birringer M. The Self-Administered Use of Complementary and Alternative Medicine (CAM) Supplements and Antioxidants in Cancer Therapy and the Critical Role of Nrf-2—A Systematic Review. Antioxidants. MDPI AG; 2022; 11:2149 10.3390/antiox11112149
• Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal Cite
  Kotsopoulos J, Lubinski J, Gronwald J, Menkiszak J, McCuaig J, Metcalfe K, et al. Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiology, Biomarkers & Prevention. American Association for Cancer Research (AACR); 2022; 31:1351-1358 10.1158/1055-9965.epi-21-1196
• Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland Cite
  Pallonen TA, Lempiäinen SMM, Joutsiniemi TK, Aaltonen RI, Pohjola PE, Kankuri-Tammilehto MK. Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland. Scientific Reports. Springer Science and Business Media LLC; 2022; 12 10.1038/s41598-022-10519-y
• Pre-diagnosis meat intake and cooking method and ovarian cancer survival: results from the Ovarian Cancer Follow-Up Study (OOPS) Cite
  Wei Y, Sun M, Wen Z, Liu F, Liu Y, Yan S, et al. Pre-diagnosis meat intake and cooking method and ovarian cancer survival: results from the Ovarian Cancer Follow-Up Study (OOPS). Food & Function. Royal Society of Chemistry (RSC); 2022; 10.1039/d1fo03825g
• Abstract P3-12-25: Risk of second primary cancers after curative treatment of breast cancer: A Korean nationwide population-based study Cite
  Kim H, Kim SS, Lee JS, Yoon JS, Shin HJ, Lee JE, et al. Abstract P3-12-25: Risk of second primary cancers after curative treatment of breast cancer: A Korean nationwide population-based study. Cancer Research. American Association for Cancer Research (AACR); 2022; 82:P3-12-25-P3-12-25 10.1158/1538-7445.sabcs21-p3-12-25
• Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer? Cite
  Lemon LS, Orr B, Modugno F, Buckanovich RJ, Coffman L, Edwards RP, et al. Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?. Gynecologic Oncology. Elsevier BV; 2022; 10.1016/j.ygyno.2022.01.022
• Dietary fish and omega-3 polyunsaturated fatty acids intake and cancer survival: A systematic review and meta-analysis Cite
  Wang Y, Liu K, Long T, Long J, Li Y, Li J, et al. Dietary fish and omega-3 polyunsaturated fatty acids intake and cancer survival: A systematic review and meta-analysis. Critical Reviews in Food Science and Nutrition. Informa UK Limited; 2022;:1-17 10.1080/10408398.2022.2029826
• Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. Cite
  Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJ, Andrieu N, et al. Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.. Apollo - University of Cambridge Repository; 2022; 10.17863/CAM.80147
• Breast cancer risk in BRCA mutation carriers after diagnosis of epithelial ovarian cancer is lower than in carriers without ovarian cancer Cite
  Nañez A, Stram DA, Bethan Powell C, Garcia C. Breast cancer risk in BRCA mutation carriers after diagnosis of epithelial ovarian cancer is lower than in carriers without ovarian cancer. Gynecologic Oncology Reports. Elsevier BV; 2022; 39:100899 10.1016/j.gore.2021.100899
• Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose–response meta-analysis of prospective studies Cite
  Byun D, Hong S, Ryu S, Nam Y, Jang H, Cho Y, et al. Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose–response meta-analysis of prospective studies. British Journal of Cancer. Springer Science and Business Media LLC; 2021; 10.1038/s41416-021-01625-1
• Family history of breast cancer as a second primary malignancy in relatives: a nationwide cohort study Cite
  Zheng G, Sundquist J, Sundquist K, Ji J. Family history of breast cancer as a second primary malignancy in relatives: a nationwide cohort study. BMC Cancer. Springer Science and Business Media LLC; 2021; 21 10.1186/s12885-021-08925-y
• Risk-Reducing Salpingo-oophorectomy (RRSO) Cite
  Kobayashi Y, Aoki D. Risk-Reducing Salpingo-oophorectomy (RRSO). Hereditary Breast and Ovarian Cancer. Springer Singapore; 2021;:183-191 10.1007/978-981-16-4521-1_12
• Potential effets of ginkgo (Ginkgo biloba, L.) on female reproduction Cite
  Sirotkin AV. Potential effets of ginkgo (Ginkgo biloba, L.) on female reproduction. Reproductive Biology. Elsevier BV; 2021; 21:100568 10.1016/j.repbio.2021.100568
• Dietary Intake of Acrylamide and Risk of Breast, Endometrial, and Ovarian Cancers: A Systematic Review and Dose–Response Meta-analysis Cite
  Adani G, Filippini T, Wise LA, Halldorsson TI, Blaha L, Vinceti M. Dietary Intake of Acrylamide and Risk of Breast, Endometrial, and Ovarian Cancers: A Systematic Review and Dose–Response Meta-analysis. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2020; 29:1095-1106 10.1158/1055-9965.epi-19-1628
• Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy Cite
  Wang C, Hu K, Deng L, He W, Fang F, Tamimi RM, et al. Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy. BMC Cancer. Springer Science and Business Media LLC; 2021; 21 10.1186/s12885-021-08132-9
• Effects of Hormone Therapy on survival, cancer, cardiovascular and dementia risks in 1.5 million women over age 65: a retrospective observational study Cite
  Baik S, McDonald C. Effects of Hormone Therapy on survival, cancer, cardiovascular and dementia risks in 1.5 million women over age 65: a retrospective observational study. Authorea, Inc.; 2021; 10.22541/au.161873076.60547427/v1
• Sugar-containing beverages and their association with risk of breast, endometrial, ovarian and colorectal cancers among Canadian women Cite
  Arthur RS, Kirsh VA, Mossavar-Rahmani Y, Xue X, Rohan TE. Sugar-containing beverages and their association with risk of breast, endometrial, ovarian and colorectal cancers among Canadian women. Cancer Epidemiology. Elsevier BV; 2020; 70:101855 10.1016/j.canep.2020.101855
• Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers Cite
  Fong A, Cass I, John C, Gillen J, Moore KM, Gangi A, et al. Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers. The American Surgeon. SAGE Publications; 2020; 86:1243-1247 10.1177/0003134820964208
• Protective Effects of Epigallocatechin Gallate (EGCG) on Endometrial, Breast, and Ovarian Cancers Cite
  Huang Y, Wang K, Chen H, Chiang Y, Hsia S. Protective Effects of Epigallocatechin Gallate (EGCG) on Endometrial, Breast, and Ovarian Cancers. Biomolecules. MDPI AG; 2020; 10:1481 10.3390/biom10111481
• Risk of primary urological and genital cancers following incident breast cancer: a Danish population-based cohort study Cite
  Sundbøll J, Farkas DK, Adelborg K, Schapira L, Tamang S, Nørgaard M, et al. Risk of primary urological and genital cancers following incident breast cancer: a Danish population-based cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 184:825-837 10.1007/s10549-020-05879-w
• Abstract C052: Premenopausal oophorectomy and survival among women with breast cancer: Evidence of effect measure modification by family history status Cite
  Roberson ML, Robinson WR, Nichols HB, Olshan AF, Troester MA. Abstract C052: Premenopausal oophorectomy and survival among women with breast cancer: Evidence of effect measure modification by family history status. Poster Presentations - Proffered Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7755.disp18-c052
• Incidence and Risk Factors of Ovarian Cancer and Breast Cancer Following Prophylactic Surgery: A Retrospective Cohort Study Cite
  Rettenmaier MA, Micha JP, Bohart R, Epstein HD, King MM, Goldstein BH. Incidence and Risk Factors of Ovarian Cancer and Breast Cancer Following Prophylactic Surgery: A Retrospective Cohort Study. Journal of Gynecologic Surgery. Mary Ann Liebert Inc; 2020; 36:189-193 10.1089/gyn.2019.0135
• Assessment of breast cancer risk in BRCA carriers with ovarian cancer: Evaluation of data from longitudinal observation. Cite
  Safra T, Waissengrin B, Gerber D, Bernstein Molho R, Amit A, Salman L, et al. Assessment of breast cancer risk in BRCA carriers with ovarian cancer: Evaluation of data from longitudinal observation.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:e13062-e13062 10.1200/jco.2019.37.15_suppl.e13062
• Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation Cite
  Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, et al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology. Elsevier BV; 2018; 150:85-91 10.1016/j.ygyno.2018.05.011
• Multiple primary non-breast tumors in breast cancer survivors Cite
  Corso G, Veronesi P, Santomauro GI, Maisonneuve P, Morigi C, Peruzzotti G, et al. Multiple primary non-breast tumors in breast cancer survivors. Journal of Cancer Research and Clinical Oncology. Springer Science and Business Media LLC; 2018; 144:979-986 10.1007/s00432-018-2621-9
• Risk of Second Primary Female Genital Malignancies in Women with Breast Cancer: a SEER Analysis Cite
  Li Z, Wu Q, Song J, Zhang Y, Zhu S, Sun S. Risk of Second Primary Female Genital Malignancies in Women with Breast Cancer: a SEER Analysis. Hormones and Cancer. Springer Science and Business Media LLC; 2018; 9:197-204 10.1007/s12672-018-0330-0
• Effect of Kumatakenin Isolated From Cloves on the Apoptosis of Cancer Cells and the Alternative Activation of Tumor-Associated Macrophages Cite
  Woo J, Ahn J, Jang DS, Lee K, Choi J. Effect of Kumatakenin Isolated From Cloves on the Apoptosis of Cancer Cells and the Alternative Activation of Tumor-Associated Macrophages. Journal of Agricultural and Food Chemistry. American Chemical Society (ACS); 2017; 65:7893-7899 10.1021/acs.jafc.7b01543
• Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of α-tocopheryl succinate-based polyphosphoester copolymers Cite
  Chen F, Zhang J, Fang X, Yu H, Liu Y, Li H, et al. Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of α-tocopheryl succinate-based polyphosphoester copolymers. Acta Pharmacologica Sinica. Springer Science and Business Media LLC; 2017; 38:859-873 10.1038/aps.2016.150
• Differences in survival for patients with familial and sporadic cancer Cite
  Lee M, Reilly M, Lindström LS, Czene K. Differences in survival for patients with familial and sporadic cancer. International Journal of Cancer. Wiley; 2016; 140:581-590 10.1002/ijc.30476
• Aspirin use and the incidence of breast, colon, ovarian, and pancreatic cancers in elderly women in the Iowa Women’s Health Study Cite
  Vaughan LE, Prizment A, Blair CK, Thomas W, Anderson KE. Aspirin use and the incidence of breast, colon, ovarian, and pancreatic cancers in elderly women in the Iowa Women’s Health Study. Cancer Causes & Control. Springer Science and Business Media LLC; 2016; 27:1395-1402 10.1007/s10552-016-0804-8
• Douching, Talc Use, and Risk of Ovarian Cancer Cite
  Gonzalez NL, O’Brien KM, D’Aloisio AA, Sandler DP, Weinberg CR. Douching, Talc Use, and Risk of Ovarian Cancer. Epidemiology. Ovid Technologies (Wolters Kluwer Health); 2016; 27:797-802 10.1097/ede.0000000000000528
• Abstract C49: Relation of family history of cancer to risk of ER+, ER-, and triple-negative breast cancer in African American women Cite
  Bethea TN, Rosenberg L, Castro-Webb N, Lunetta KL, Sucheston LE, Ruiz-Narvaez EA, et al. Abstract C49: Relation of family history of cancer to risk of ER+, ER-, and triple-negative breast cancer in African American women. Organ Site Research. American Association for Cancer Research; 2016; 10.1158/1538-7755.disp15-c49
• Endocrine disrupting chemicals (EDCs) and female cancer: Informing the patients Cite
  Rachoń D. Endocrine disrupting chemicals (EDCs) and female cancer: Informing the patients. Reviews in Endocrine and Metabolic Disorders. Springer Science and Business Media LLC; 2015; 16:359-364 10.1007/s11154-016-9332-9
• Effects of Flaxseed Lignan Secoisolariciresinol Diglucosideon Preneoplastic Biomarkers of Cancer Progression in a Model of Simultaneous Breast and Ovarian Cancer Development Cite
  Delman DM, Fabian CJ, Kimler BF, Yeh H, Petroff BK. Effects of Flaxseed Lignan Secoisolariciresinol Diglucosideon Preneoplastic Biomarkers of Cancer Progression in a Model of Simultaneous Breast and Ovarian Cancer Development. Nutrition and Cancer. Informa UK Limited; 2015; 67:857-864 10.1080/01635581.2015.1042549
• Dietary Cadmium Exposure and Risk of Breast, Endometrial, and Ovarian Cancer in the Women’s Health Initiative Cite
  Adams SV, Quraishi SM, Shafer MM, Passarelli MN, Freney EP, Chlebowski RT, et al. Dietary Cadmium Exposure and Risk of Breast, Endometrial, and Ovarian Cancer in the Women’s Health Initiative. Environmental Health Perspectives. Environmental Health Perspectives; 2014; 122:594-600 10.1289/ehp.1307054
• Low Concentration of Quercetin Antagonizes the Cytotoxic Effects of Anti-Neoplastic Drugs in Ovarian Cancer Cite
  Li N, Sun C, Zhou B, Xing H, Ma D, Chen G, et al. Low Concentration of Quercetin Antagonizes the Cytotoxic Effects of Anti-Neoplastic Drugs in Ovarian Cancer. PLoS ONE. Public Library of Science (PLoS); 2014; 9:e100314 10.1371/journal.pone.0100314
• Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis Cite
  Friebel TM, Domchek SM, Rebbeck TR. Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2014; 106 10.1093/jnci/dju091
• Myricetin induces apoptosis and enhances chemosensitivity in ovarian cancer cells Cite
  Zheng A, Chen Y, Zhao L, Feng J. Myricetin induces apoptosis and enhances chemosensitivity in ovarian cancer cells. Oncology Letters. Spandidos Publications; 2017; 13:4974-4978 10.3892/ol.2017.6031
• Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE Cite
  Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2013; 105:812-822 10.1093/jnci/djt095
• Dietary folates and cancer risk in a network of case–control studies Cite
  Tavani A, Malerba S, Pelucchi C, Dal Maso L, Zucchetto A, Serraino D, et al. Dietary folates and cancer risk in a network of case–control studies. Annals of Oncology. Elsevier BV; 2012; 23:2737-2742 10.1093/annonc/mds212
• 25(OH)D3 in patients with ovarian cancer and its correlation with survival Cite
  Walentowicz-Sadlecka M, Grabiec M, Sadlecki P, Gotowska M, Walentowicz P, Krintus M, et al. 25(OH)D3 in patients with ovarian cancer and its correlation with survival. Clinical Biochemistry. Elsevier BV; 2012; 45:1568-1572 10.1016/j.clinbiochem.2012.07.110
• Increased Risk for Second Primary Malignancies in Women with Breast Cancer Diagnosed at Young Age: A Population-Based Study in Taiwan Cite
  Lee K, Chen S, Chan CH, Lu C, Chen C, Lin J, et al. Increased Risk for Second Primary Malignancies in Women with Breast Cancer Diagnosed at Young Age: A Population-Based Study in Taiwan. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2008; 17:2647-2655 10.1158/1055-9965.epi-08-0109
• Second primary breast, endometrial, and ovarian cancers in Black and White breast cancer survivors over a 35-year time span: effect of age Cite
  Nsouli-Maktabi HH, Henson DE, Younes N, Young HA, Cleary SD. Second primary breast, endometrial, and ovarian cancers in Black and White breast cancer survivors over a 35-year time span: effect of age. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 129:963-969 10.1007/s10549-011-1560-9
• Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden Cite
  Attner B, Landin-Olsson M, Lithman T, Noreen D, Olsson H. Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. Cancer Causes & Control. Springer Science and Business Media LLC; 2012; 23:769-777 10.1007/s10552-012-9946-5
• Cruciferous vegetables and cancer risk in a network of case–control studies Cite
  Bosetti C, Filomeno M, Riso P, Polesel J, Levi F, Talamini R, et al. Cruciferous vegetables and cancer risk in a network of case–control studies. Annals of Oncology. Elsevier BV; 2012; 23:2198-2203 10.1093/annonc/mdr604
• Oral contraceptives and risk of ovarian and breast cancers inBRCAmutation carriers: a meta-analysis Cite
  Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers inBRCAmutation carriers: a meta-analysis. Expert Review of Anticancer Therapy. Informa UK Limited; 2011; 11:1197-1207 10.1586/era.11.38
• P2-13-02: Parent of Origin of BRCA Mutation May Determine Age at Breast Cancer Diagnosis. Cite
  Shapira I, Budman D, Akerman M, Weiselberg L, Vinciguerra V, D'Olimpio J, et al. P2-13-02: Parent of Origin of BRCA Mutation May Determine Age at Breast Cancer Diagnosis.. Poster Session Abstracts. American Association for Cancer Research; 2011; 10.1158/0008-5472.sabcs11-p2-13-02
• Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: Findings From the Breast Cancer Family Registry Cite
  Kurian AW, Gong GD, John EM, Johnston DA, Felberg A, West DW, et al. Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: Findings From the Breast Cancer Family Registry. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:4505-4509 10.1200/jco.2010.34.4440
• Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers Cite
  Bernholtz S, Jakobson-Setton A, Korach J, Ben Baruch G, Laitman Y, Friedman E. Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 131:981-985 10.1007/s10549-011-1807-5
• Dietary transfatty acids and cancer risk Cite
  Hu J, Vecchia CL, de Groh M, Negri E, Morrison H, Mery L. Dietary transfatty acids and cancer risk. European Journal of Cancer Prevention. Ovid Technologies (Wolters Kluwer Health); 2011; 20:530-538 10.1097/cej.0b013e328348fbfb
• Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations Cite
  Dite GS, Whittemore AS, Knight JA, John EM, Milne RL, Andrulis IL, et al. Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations. British Journal of Cancer. Springer Science and Business Media LLC; 2010; 103:1103-1108 10.1038/sj.bjc.6605876
• Analgesic Use and Sex Steroid Hormone Concentrations in Postmenopausal Women Cite
  Gates MA, Tworoger SS, Eliassen AH, Missmer SA, Hankinson SE. Analgesic Use and Sex Steroid Hormone Concentrations in Postmenopausal Women. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2010; 19:1033-1041 10.1158/1055-9965.epi-09-0975
• Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age Cite
  van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJE, de Vries J, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 124:643-651 10.1007/s10549-010-0805-3
• Antibiotic use predicts an increased risk of cancer Cite
  Kilkkinen A, Rissanen H, Klaukka T, Pukkala E, Heliövaara M, Huovinen P, et al. Antibiotic use predicts an increased risk of cancer. International Journal of Cancer. Wiley; 2008; 123:2152-2155 10.1002/ijc.23622
• Cancer incidence in British vegetarians Cite
  Key TJ, Appleby PN, Spencer EA, Travis RC, Allen NE, Thorogood M, et al. Cancer incidence in British vegetarians. British Journal of Cancer. Springer Science and Business Media LLC; 2009; 101:192-197 10.1038/sj.bjc.6605098
• Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening Cite
  Smith A, Moran A, Boyd MC, Bulman M, Shenton A, Smith L, et al. Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. Journal of Medical Genetics. BMJ; 2006; 44:10-15 10.1136/jmg.2006.043091
• Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2 Cite
  Domchek SM, Gaudet MM, Stopfer JE, Fleischaut MH, Powers J, Kauff N, et al. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 119:409-414 10.1007/s10549-009-0611-y
• Dietary intake and breast density in high-risk women: a cross-sectional study Cite
  Tseng M, Byrne C, Evers KA, Daly MB. Dietary intake and breast density in high-risk women: a cross-sectional study. Breast Cancer Research. Springer Science and Business Media LLC; 2007; 9 10.1186/bcr1781
• Breast and Ovarian Cancer in Relatives of Cancer Patients, with and without BRCA Mutations Cite
  Lee JS, John EM, McGuire V, Felberg A, Ostrow KL, DiCioccio RA, et al. Breast and Ovarian Cancer in Relatives of Cancer Patients, with and without BRCA Mutations. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2006; 15:359-363 10.1158/1055-9965.epi-05-0687
• A two-step screening method, using estrogen receptor-mediated transactivation, to measure estrogenicity in edible plants Cite
  Arao Y, Kanamori N, Kikkawa E, Otsuka H, Arimoto Y, Ikeda K, et al. A two-step screening method, using estrogen receptor-mediated transactivation, to measure estrogenicity in edible plants. Food Chemistry. Elsevier BV; 2007; 104:1288-1294 10.1016/j.foodchem.2007.01.076
• Milk and lactose intakes and ovarian cancer risk in the Swedish Mammography Cohort Cite
  Larsson SC, Bergkvist L, Wolk A. Milk and lactose intakes and ovarian cancer risk in the Swedish Mammography Cohort. The American Journal of Clinical Nutrition. Oxford University Press (OUP); 2004; 80:1353-1357 10.1093/ajcn/80.5.1353
• Onion and garlic use and human cancer Cite
  Galeone C, Pelucchi C, Levi F, Negri E, Franceschi S, Talamini R, et al. Onion and garlic use and human cancer. The American Journal of Clinical Nutrition. Oxford University Press (OUP); 2006; 84:1027-1032 10.1093/ajcn/84.5.1027
• Diet and Risk of Ovarian Cancer in the California Teachers Study Cohort Cite
  Chang ET, Lee VS, Canchola AJ, Clarke CA, Purdie DM, Reynolds P, et al. Diet and Risk of Ovarian Cancer in the California Teachers Study Cohort. American Journal of Epidemiology. Oxford University Press (OUP); 2007; 165:802-813 10.1093/aje/kwk065